MSB 1.30% $1.14 mesoblast limited

One very interesting comment in the article from a...

  1. 236 Posts.
    lightbulb Created with Sketch. 120
    One very interesting comment in the article from a physician/scientist --
    Researchers have been looking — without success — at targeted ways to dampen immune responses in critically ill people for decades, says Angus. “And we have 20 to 30 years of failing to improve outcome with therapies that try to block the cytokine cascade.”
    This really tells you how big MSB's program is -- success would be a game changer for the treatment of inflammation.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.